ACS chemical neuroscience molecule spotlight on suvorexant

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.

Original languageEnglish (US)
Pages (from-to)647-648
Number of pages2
JournalACS Chemical Neuroscience
Volume3
Issue number9
DOIs
StatePublished - Sep 19 2012

Fingerprint

Phase III Clinical Trials
Neurosciences
Sleep
Placebos
Molecules
Pharmaceutical Preparations
Modulation
suvorexant

Keywords

  • Sleep
  • bioavailability (F)
  • insomnia
  • novel mechanism
  • orexin antagonist

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

ACS chemical neuroscience molecule spotlight on suvorexant. / Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 3, No. 9, 19.09.2012, p. 647-648.

Research output: Contribution to journalReview article

@article{42412218a63943db9bd28a500f6e77de,
title = "ACS chemical neuroscience molecule spotlight on suvorexant",
abstract = "Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.",
keywords = "Sleep, bioavailability (F), insomnia, novel mechanism, orexin antagonist",
author = "Hopkins, {Corey R.}",
year = "2012",
month = "9",
day = "19",
doi = "10.1021/cn300086a",
language = "English (US)",
volume = "3",
pages = "647--648",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on suvorexant

AU - Hopkins, Corey R.

PY - 2012/9/19

Y1 - 2012/9/19

N2 - Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.

AB - Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.

KW - Sleep

KW - bioavailability (F)

KW - insomnia

KW - novel mechanism

KW - orexin antagonist

UR - http://www.scopus.com/inward/record.url?scp=84866431931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866431931&partnerID=8YFLogxK

U2 - 10.1021/cn300086a

DO - 10.1021/cn300086a

M3 - Review article

C2 - 23024835

AN - SCOPUS:84866431931

VL - 3

SP - 647

EP - 648

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 9

ER -